ESTRO 2024 - Abstract Book

S1658

Clinical - Lung

ESTRO 2024

[1] Banfill K, Giuliani M, Aznar M, Franks K, McWilliam A, Schmitt M, Sun F, Vozenin MC, Faivre Finn C on behalf of the IASLC ART group. Cardiac Toxicity of Thoracic Radiotherapy: Existing Evidence and Future Directions. JTO 2021, 16(2), 216-227 [2] Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 2022;43:4229 – 361

[3] Abravan A, Faivre-Finn C, Kennedy J, McWilliam A, van Herk M. Radiotherapy-Related Lymphopenia Affects Overall Survival in Patients With Lung Cancer. Journal of Thoracic Oncology 2020;15:1624 – 35.

[4] Duane F, Aznar MC, Bartlett F, Cutter DJ, Darby SC, Jagsi R, et al. A cardiac contouring atlas for radiotherapy. Radiotherapy and Oncology 2017;122:416 – 22.

1328

Digital Poster

How are we doing in the “caution -fly- zone”? Central and ultracentral lung tumors

M.Ujué Ruiz 1 , Sonia Flamarique 1 , Mikel Rico 1 , Erkuden Burillo 1 , Libe Amondarain 1 , Darwin Enrique Pozo 1 , Sara lopez 1 , Marisa Fernandez 1 , Maria Isabel Martinez 1 , Patricia Lorenzana 1 , Katty Zavala 1 , Ignacio Visus 1 , Irene Martinez 1 , Anna Paola Jablonska 1 , Victor de la Llana 2 , Fernando Mañeru 2 , Santiago Pellejero 2 , Enrique Martinez 1 1 Hospital Universitario de Navarra, Radiation Oncology, Pamplona, Spain. 2 Hospital Universitario de Navarra, Physicist, Pamplona, Spain

Purpose/Objective:

Due to the higher toxicity that showed Stereotactic Body Radiotherapy (SBRT) for central and ultracentral lung tumors, RT schemes have evolved in order to be safer. We want to find out how are our patients doing in terms of toxicity, local control and survival. In addition, we have compared both populations since we used different RT schemes for each one.

Material/Methods:

This was a retrospective review of patients with primary and metastatic lung tumors treated with SBRT or hypofractionated RT from 2012 to 2023. Patients were included if they had central lesions (defined as tumors less than 2 cm far from the proximal bronchial tree or within 2 cm of mediastinal structures) and ultracentral lesions (defined as tumors abutting the proximal bronchial tree). Most of the times, at our centre, central tumors are treated with a regimen of SBRT 60 Gy (8 x 7.5 Gy) and ultracentral tumors with an hypofractionation of 60 Gy (15 x 4 Gy). Demographic data were collected. The 1 and 2-year overall survival (OS), 2-year local failure-free (LF), 2-year